MYUNGMOON PHARM CO.,LTD Logo

MYUNGMOON PHARM CO.,LTD

Develops, manufactures, and commercializes prescription & OTC medicines for global markets.

017180 | KO

Overview

Corporate Details

ISIN(s):
KR7017180001
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약공단2길 26, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Myungmoon Pharm. Co., Ltd., established in 1983, is a research-based pharmaceutical company engaged in the development, manufacturing, and commercialization of healthcare products. The company's portfolio includes a range of ethical (ETC) prescription drugs and over-the-counter (OTC) medicines. It operates through the entire pharmaceutical value chain, from research and development to the import, export, and distribution of its products. Myungmoon Pharm serves both the domestic South Korean market and international markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-06-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 25.7 KB
2025-03-26 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 20.8 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.8 MB
2025-03-14 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 206.9 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.7 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 222.5 KB
2025-03-10 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 203.2 KB
2025-02-19 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 14.1 KB
2025-01-09 00:00
Regulatory News Service
신탁계약해지결과보고서
Korean 21.4 KB
2025-01-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 25.7 KB
2024-11-20 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 3.9 KB

Automate Your Workflow. Get a real-time feed of all MYUNGMOON PHARM CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MYUNGMOON PHARM CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MYUNGMOON PHARM CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.